Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AC-101 in Moderate to Severe Active Ulcerative Colitis
NCT07083193Phase 2Completed
- Sponsor
- Accro Bioscience
- Start
- Jan 2025
- Primary completion
- Apr 2026
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of AC-101 in ulcerative colitis (UC), sponsored by Accro Bioscience. Started Jan 2025; status: completed.
02
Drugs
AC-101
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT07083193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07083193.